Essential Tremor: Classification & Diagnosis
Essential tremor (ET) is the most common pathological tremor and one of the most prevalent movement disorders, affecting an estimated 25 million people worldwide. Long dismissed as a benign, monosymptomatic condition, ET is now recognized as a complex, heterogeneous syndrome with cerebellar pathology, cognitive implications, and significant functional disability. The 2018 MDS Consensus Statement on the Classification of Tremors fundamentally restructured how ET is defined and diagnosed, introducing a two-axis classification system and the controversial “ET Plus” category. This article reviews current classification, diagnostic criteria, epidemiology, differential diagnosis, biomarkers, neuropathology, and genetics of essential tremor.
Bottom Line
- MDS 2018 criteria: ET requires bilateral upper limb action tremor of ≥3 years duration, with no other neurological signs; ET Plus adds “soft signs of uncertain significance” (impaired tandem gait, rest tremor, questionable dystonia)
- Epidemiology: Global prevalence ~0.3–1.3% overall, rising steeply with age (2.9% in those ≥80); bimodal onset with peaks in the 20s and 60s–70s; ~7 million affected in the US alone
- Key differential: Parkinson disease tremor (4–6 Hz, rest-predominant, re-emergent with ~9-second latency), enhanced physiologic tremor (8–12 Hz, no head tremor, resolves with trigger removal), dystonic tremor (irregular, position-dependent, “null point”)
- Diagnostic biomarkers: DaTscan (normal in ET, abnormal in PD), alpha-synuclein SAA (negative biomarker for ET), FMR1 testing (FXTAS screen), electrophysiology/accelerometry for frequency analysis
- Neuropathology: Cerebellar Purkinje cell loss (15% lower density) in ~75% of ET brains; Lewy body variant (LBVET) with locus coeruleus pathology in ~25%
- Genetics: Highly heritable (45–90%) but polygenic; no single causative gene identified despite ETM1–4 linkage loci and GWAS hits (LINGO1, STK32B, CTNNA3)
MDS 2018 Classification of Tremors
The 2018 International Parkinson and Movement Disorder Society (MDS) Consensus Statement (Bhatia et al.) replaced the 1998 classification system with a two-axis framework that reconceptualized tremor disorders, including ET, as syndromes rather than discrete disease entities.
Axis 1: Clinical Features
Axis 1 describes clinical characteristics across four domains:
| Domain | Components |
|---|---|
| Historical features | Age at onset, family history, temporal evolution (static, progressive, stepwise) |
| Tremor characteristics | Body distribution, activation condition (rest, postural, kinetic, intention, task-specific, position-specific) |
| Associated signs | Systemic findings (thyrotoxicosis, drug exposure) and neurological signs (dystonia, parkinsonism, ataxia, neuropathy) |
| Laboratory tests | Electrophysiology, neuroimaging, fluid biomarkers |
Axis 2: Etiology
- Acquired: Drug-induced, toxic, metabolic, traumatic, vascular
- Genetic: Autosomal dominant, recessive, or complex inheritance
- Idiopathic: When no etiology is identified (most ET cases)
Diagnostic Criteria for Essential Tremor
The MDS 2018 criteria define ET as an isolated tremor syndrome with the following requirements:
MDS 2018 Diagnostic Criteria for ET
- Bilateral upper limb action tremor (postural and/or kinetic)
- Duration of at least 3 years
- With or without tremor in other locations (head, voice, lower limbs)
- Absence of other neurological signs such as dystonia, ataxia, or parkinsonism
Exclusion criteria:
- Isolated focal tremors (voice only, head only)
- Orthostatic tremor with frequency >12 Hz
- Task-specific or position-specific tremors
- Sudden onset or stepwise deterioration
Essential Tremor Plus (ET Plus)
ET Plus was introduced as a separate classification (not a subtype of ET) for patients who meet all criteria for ET but also exhibit additional neurological signs of uncertain significance:
| Soft Sign | Prevalence in ET | Notes |
|---|---|---|
| Impaired tandem gait | ~50% of ET patients | Also seen in 28% of controls; 71% of patients >70 years vs. 7.4% under 70 years |
| Rest tremor | <15% clinic / <5% population | Low-amplitude; does not meet criteria for parkinsonism |
| Questionable dystonic posturing | Variable | Boundary between “questionable” and “definite” dystonia is poorly defined |
| Mild cognitive impairment | ~27% cumulative | Executive dysfunction and memory deficits |
Disease Stage vs. Distinct Category: The Debate
ET Plus as a disease stage (continuum model): Many soft signs increase with age and disease duration, suggesting that patients with classical ET may evolve to ET Plus over time. Longitudinal data support progressive accumulation of soft signs.
ET Plus as a distinct category: The MDS explicitly defines ET Plus as a separate classification, not a subtype of ET. It functions as a diagnostic placeholder acknowledging uncertainty. The presence of rest tremor or subtle dystonia may reflect distinct underlying pathology, and postmortem studies show heterogeneous pathological subtypes.
Practical Limitations of ET Plus
Soft signs have poor inter-rater reliability and low diagnostic sensitivity/specificity. The boundary between “questionable” and “definite” dystonia is not clearly defined, leading to diagnostic inconsistency — one examiner may classify as ET Plus while another diagnoses dystonic tremor. A Bayesian interpretation framework has been proposed to estimate the probability that soft signs indicate an alternative diagnosis.
Epidemiology
Global Prevalence
| Measure | Estimate | Source |
|---|---|---|
| Global pooled prevalence (29 studies, 2001–2019) | 0.32% (95% CI: 0.12–0.91) | 2021 meta-analysis |
| Estimated worldwide cases | ~24.9 million (range 9.5–70.9 million) | 2021 meta-analysis |
| All-ages pooled prevalence | ~1.33% | Earlier pooled analysis |
| US estimated cases | ~7 million | Continuum 2025 |
| Geographic range | 0.2% (Singapore) to 8.6% (parts of Spain) | Regional studies |
Age-Specific Prevalence
| Age Group | Male | Female | Overall |
|---|---|---|---|
| <20 years | 0.04% | 0.03% | 0.04% |
| 20–29 | 0.10% | 0.07% | 0.09% |
| 40–49 | 0.33% | 0.23% | 0.28% |
| 60–69 | 1.06% | 0.73% | 0.89% |
| 70–79 | 1.86% | 1.28% | 1.54% |
| ≥80 years | 3.48% | 2.49% | 2.87% |
Age of Onset
ET has a classically described bimodal age of onset with peaks in the second–third decade and sixth–seventh decade. However, population-based studies show a dominant late-life peak (85.9% of cases) with only a small early peak (14.1% at age ≤30). The more pronounced bimodal pattern seen in tertiary centers likely reflects referral bias toward familial young-onset cases.
Sex and Ethnicity
Males show consistently higher prevalence across all age groups (0.36% vs. 0.28% overall). In the multiethnic Washington Heights-Inwood study, Hispanic ethnicity was associated with higher odds of ET (OR = 2.19 vs. whites), while non-white patients had higher mean tremor scores. Head tremor was absent in African American subjects (0%) but present in 25% of white and 29% of Hispanic patients. Significant disparities exist in DBS access across racial groups.
Clinical Evaluation
History
A detailed history should address:
- Age of onset and duration: ET requires ≥3 years of bilateral UL tremor; onset <40 years suggests familial ET, FXTAS (if male >50 with CGG 55–200), or Wilson disease (if <40 with liver/neuro findings)
- Temporal pattern: Gradual progressive (ET, PD) vs. sudden onset (vascular, psychogenic) vs. stepwise (drug-related, metabolic)
- Distribution: Bilateral symmetric (ET) vs. unilateral onset (PD); hand-predominant vs. head/voice involvement
- Activation: Action/postural predominant (ET) vs. rest predominant (PD) vs. intention (cerebellar)
- Functional impact: Difficulty eating, drinking, writing, dressing; social embarrassment; early retirement
- Family history: Autosomal dominant in ~50% of ET cases
- Medication review: SSRIs, lithium, valproate, beta-agonists, amiodarone, thyroid hormones, stimulants
- Alcohol responsiveness: ~50–70% of ET patients report transient improvement with alcohol (not specific to ET; dystonic tremor may also respond)
Examination Maneuvers
| Maneuver | What It Tests | Key Observations |
|---|---|---|
| Arms at rest | Rest tremor | Hands resting in lap or on armrest; rest tremor suggests PD (pill-rolling, 4–6 Hz) or advanced ET |
| Arms outstretched (forward extension) | Postural tremor | Arms extended horizontally, fingers spread; note latency — immediate onset = ET; ~9-second delay = re-emergent PD tremor |
| Wing-beating posture | Postural tremor (lateral) | Elbows flexed at 90°, fists facing each other; elicits proximal tremor; elbow flexion posture may suppress re-emergent PD tremor |
| Finger-to-nose | Kinetic/intention tremor | Note whether tremor worsens approaching the target (intention = cerebellar) or is roughly constant throughout (kinetic = ET) |
| Spiral drawing | Kinetic tremor amplitude | Pre-drawn spirals provide documented severity; serial comparison tracks progression; Archimedes spiral is TETRAS item 6 |
| Handwriting sample | Kinetic tremor, micrographia | ET = large, tremulous script; PD = micrographia (progressively smaller); dystonia = irregular pressure/slant |
| Pouring water between cups | Functional kinetic tremor | Practical measure of tremor severity; correlates well with ADL impairment |
| Head/voice assessment | Head/vocal tremor | Observe head tremor at rest and during conversation; sustained phonation “ahhh” for voice tremor; head tremor in ET resolves when supine (persists in PD) |
| Tandem gait | Cerebellar function | Impaired in ~50% of ET (ET Plus criterion); disproportionate impairment suggests cerebellar ataxia, not ET |
Assessment Scales
TETRAS (The Essential Tremor Rating Assessment Scale)
Developed by the Tremor Research Group as a rapid, equipment-free clinical assessment tool with objective metric anchors.
- Structure: Three subscales — Activities of Daily Living (ADL, 12 items), Performance (9 items), Socioeconomic impact
- Performance subscale (9 items): Head, face, voice, upper limb (sum of 3 maneuvers × 2 limbs = range 0–24), lower limb, spiral, handwriting, dot approximation, standing
- Scoring: 0–4 in half-point increments; maximum total = 64 points
- Reliability: ICC for total tremor score = 0.95 (excellent); ICCs >0.95 for all components except heel-to-shin
Fahn-Tolosa-Marin (FTM) Clinical Rating Scale
The most widely used tremor scale in clinical trials.
- Part A: Rest and action tremor at body sites (0–4 amplitude grading); maximum 80
- Part B: Kinetic function tasks (writing, spirals, line drawing, pouring); maximum 36
- Part C: Functional disability (speaking, eating, drinking, hygiene, dressing, writing, working); maximum 28
- Total maximum: 144 points
- Limitation: Amplitude anchors for grade 4 (>4 cm) may be too low for patients with severe tremor
WHIGET Tremor Rating Scale
Designed for population-based epidemiological studies. A 23-item videotaped examination assessing rest, postural, and kinetic tremor across 6 tasks with substantial agreement with TETRAS ratings.
Differential Diagnosis
| Condition | Frequency | Activation | Key Distinguishing Features |
|---|---|---|---|
| Enhanced physiologic tremor | 8–12 Hz | Postural | Low amplitude, fine; no head tremor; resolves with trigger removal; frequency shifts with weight loading (unlike ET); no family history |
| Parkinson disease | 4–6 Hz | Rest (pill-rolling) | Unilateral onset; re-emergent postural tremor with ~9-second latency (vs. 1 second in ET); increases during walking (decreases in ET); associated bradykinesia, rigidity; reduced olfaction (UPSIT 25 = 83% sensitivity, 94% specificity); head tremor persists supine (resolves in ET) |
| Dystonic tremor | 4–7 Hz, irregular | Position-dependent | Disappears at “null point” (when body part assumes dystonic posture); irregular amplitude; geste antagoniste; associated abnormal posturing; directionality of head tremor (vs. oscillatory in ET) |
| Drug-induced tremor | High, fine | Postural | Temporal relationship to drug; resolves with withdrawal; common culprits: SSRIs, lithium, valproate, beta-agonists, amiodarone |
| Neuropathic tremor | 3–6 Hz | Postural, kinetic | Associated neuropathy (CIDP, CMT1A, anti-MAG); higher Tremor Stability Index (2.1 vs. 1.4 in ET, p=0.007); may respond to immunotherapy |
| Functional tremor | Variable | Any | Abrupt onset; distractibility (tremor ceases with distraction); entrainment (frequency shifts to match contralateral tapping); inconsistent patterns; dramatic fluctuation |
| Holmes tremor | 2–4 Hz, coarse | Rest + postural + intention | Always has identifiable structural lesion (midbrain/thalamus on MRI); proximal, unilateral; develops weeks–months after causative event |
| Cerebellar tremor | 3–4 Hz | Intention | Worsens approaching target (terminal dysmetria); associated ataxia, dysarthria, nystagmus; ipsilateral to lesion; absent at rest |
The ET vs. PD Tremor Diagnostic Challenge
Re-emergent postural tremor is the most useful clinical feature for distinguishing PD from ET. In PD, when the arms are extended, there is a characteristic latency of approximately 9 seconds before tremor emerges (reflecting the time for the central oscillator to overcome volitional suppression), whereas ET tremor appears within 1 second. Additionally, the kinetic-to-postural tremor amplitude ratio is informative: in ET, kinetic tremor exceeds postural by approximately 6–7 times, while in PD the opposite pattern occurs. DaTscan can confirm the diagnosis when clinical features are ambiguous, though up to 30% of ET cases may show mild DAT abnormalities.
Diagnostic Biomarkers
DaTscan (Dopamine Transporter SPECT)
- Indication: Clinical uncertainty between ET and PD (rest tremor, asymmetry, subtle parkinsonian features)
- Mechanism: Ioflupane I-123 images striatal dopamine transporters; PD shows reduced uptake, ET typically normal
- Sensitivity/specificity: High for distinguishing PD from ET; cannot differentiate among parkinsonian syndromes (PD, MSA, PSP, CBS)
- Limitation: Up to 30% of ET cases may show mild striatal DAT abnormalities, reducing specificity in borderline cases
Alpha-Synuclein Seed Amplification Assay (SAA)
- Performance: ~86% sensitivity, ~92% specificity for alpha-synucleinopathies (PD, DLB, MSA)
- Samples: CSF (highest accuracy), skin biopsy, blood, olfactory mucosa
- Relevance to ET: SAA serves as a negative biomarker — a positive result in a patient with presumed ET suggests an underlying synucleinopathy (prodromal PD or DLB)
- Potential: Could identify ET Plus patients at risk of converting to PD, particularly those with rest tremor and anosmia
FMR1/FXTAS Testing
- When to test: Males >50 years with progressive action tremor and cerebellar ataxia, especially with cognitive decline, neuropathy, dysautonomia; family history of intellectual disability, premature ovarian failure, or autism
- Test: PCR for CGG repeats in FMR1 gene; premutation range = 55–200 CGG repeats
- FXTAS features: Onset in 60s; action/intention tremor followed by cerebellar gait ataxia; MRI shows characteristic middle cerebellar peduncle (MCP) white matter lesions
Electrophysiology and Accelerometry
- Polymyography: Surface EMG + accelerometry; standard tremor characterization technique
- Frequency analysis: ET = 4–11 Hz with synchronous antagonist activity; PD = 4–6 Hz with alternating activity
- Weight-loading test: EPT frequency shifts with added weight; ET and PD frequencies remain constant
- Tremor Stability Index (TSI): Distinguishes neuropathic tremor (higher TSI) from ET (lower TSI)
- Diagnostic accuracy: Frequency-domain discrimination achieves ~93.9% accuracy between physiologic and pathological tremor
Neuropathology
Postmortem studies suggest that ET brains are not pathologically homogeneous, though the existence and magnitude of cerebellar Purkinje cell loss remain debated. Two main pathological subtypes have been identified:
Cerebellar ET (~75% of cases)
| Finding | Details |
|---|---|
| Purkinje cell loss | Meta-analysis of 215 ET brains: 15.0% lower linear density and 37.8% higher empty basket percentage vs. controls; up to 38.2% reduction in severely affected cases |
| Torpedoes | Axonal swellings (fusiform neurofilament accumulations) in degenerating Purkinje cells; 10-fold increase vs. age-matched controls |
| Bergmann gliosis | Proliferation of Bergmann glial cells in response to Purkinje cell degeneration |
| Heterotopic Purkinje cells | Cells displaced into the molecular layer (developmental or degenerative) |
| Dendritic abnormalities | Abnormal swellings indicating early dendritic degeneration |
Importantly, Purkinje cell decline in ET is not driven by coexistent Alzheimer pathology, Lewy pathology, or clinical confounders (meta-analysis, 2026).
Lewy Body Variant of ET (LBVET, ~25% of cases)
- Lewy bodies confined primarily to the locus coeruleus (LC), with relatively preserved cerebellar tissue
- Distinct from the brainstem-predominant PD staging pattern (where Lewy pathology is more widespread)
- Accompanied by LC neuronal depletion
- The significance remains debated — whether LBVET is a distinct disease, incidental co-pathology, or a bridge between ET and PD
Genetics
ET is highly heritable (45–90% from twin and family studies) with autosomal dominant inheritance in roughly half of families, yet no single causative gene has been definitively identified.
Linkage-Based Loci
| Locus | Chromosome | Status |
|---|---|---|
| ETM1 | 3q13 | Icelandic families; near DRD3 gene; causal gene unidentified; not independently confirmed |
| ETM2 | 2p24.1 | Only locus with conclusive single-family linkage (LOD >3.3); causal gene unidentified |
| ETM3 | 6p23 | Genome-wide linkage scan; causal gene unidentified |
| ETM4 | 16p11 (FUS gene) | Rare FUS/TLS mutations (p.Arg216Cys, p.Pro431Leu, p.R377W); FUS involved in RNA processing/DNA repair |
GWAS-Identified Genes
| Gene | Chromosome | OR | Significance |
|---|---|---|---|
| LINGO1 | 15q24.3 | 1.63 | First ET GWAS hit (rs9652490); confirmed in meta-analysis; replication inconsistent across populations |
| CTNNA3 | — | 1.17 | Genome-wide significance in combined analysis (rs12764057, p = 1.19 × 10-8) |
| STK32B | 4p16.2 | 0.77 (protective) | 2,807 ET cases vs. 6,441 controls; meta-analysis OR 0.80 |
| PPARGC1A | 22 | 0.75 (protective) | Replicated in Asian populations |
| LINGO2 | — | 1.50–1.56 | Influences age at onset (4–5 years earlier); Asian cohorts |
A comprehensive review of 74 studies analyzing over 50 genes and loci concluded that ET susceptibility involves multiple genes with small individual effects (polygenic architecture) interacting with environmental factors. Collaborative, multiethnic, large-scale GWAS are needed to resolve the genetic basis.
Key References
- Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33(1):75–87.
- Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. 2010;25(5):534–541.
- Louis ED. The evolving definition of essential tremor: what are we dealing with? Parkinsonism Relat Disord. 2018;46(Suppl 1):S87–S91.
- Kerridge CA, et al. Purkinje cell loss in essential tremor brains: meta-analysis of 215 brains over 21 years. Ann Clin Transl Neurol. 2026.
- Haubenberger D, Hallett M. Essential tremor. N Engl J Med. 2018;378(19):1802–1810.
- Clark LN, Louis ED. Essential tremor. Handb Clin Neurol. 2018;147:229–239.
- Hopfner F, Deuschl G. Managing essential tremor. Neurotherapeutics. 2020;17(4):1603–1621.
- Shanker V. Essential tremor: diagnosis and management. BMJ. 2019;366:l4485.